Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 24;8(60):101215-101223.
doi: 10.18632/oncotarget.20538. eCollection 2017 Nov 24.

High mobility group protein B1 is a predictor of poor survival in ovarian cancer

Lee R Machado  1   2   3 , Paul M Moseley  4 , Robert Moss  5 , Suha Deen  6 , Christopher Nolan  5 , Ian Spendlove  5 , Judith M Ramage  5 , Stephen Yt Chan  4 , Lindy G Durrant  5
Affiliations

High mobility group protein B1 is a predictor of poor survival in ovarian cancer

Lee R Machado et al. Oncotarget. .

Abstract

High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was assessed by immunohistochemistry in two independent cohorts (n=194 and n=360) using a monoclonal antibody specific for HMGB1. Kaplan-Meier analysis showed an association of HMGB1 expression with progression free survival in the primary cohort (p=0.023). In the validation cohort, expression was associated with overall survival (p=0.002). Low expression of HMGB1 was protective and in a multivariate model HMGB1 expression was shown to be an independent predictor of poor survival in ovarian cancer (p=0.006). The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients.

Keywords: DAMP; HMGB1; autophagy; ovarian cancer; prognostic.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1. Representative photomicrographs of ovarian TMA cores immunohistochemically stained for HMGB1 from Nottingham cohort (cut point >42)
The level of expression ranged from (A) Negative (H-score 0), (B) Weak (H-score 14), (C) Intermediate (H-score 167) and (D) Strong expression (H-score 213).
Figure 2
Figure 2
Kaplan Meier curves showing overall survival in (A) the Derby cohort and (B) overall survival and (C) progression free survival in ovarian cancer patients in the Nottingham cohort.
See this image and copyright information in PMC

References

    1. Lowe KA, Chia VM, Taylor A, O’Malley C, Kelsh M, Mohamed M, Mowat FS, Goff B. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130:107–14. https://doi.org/10.1016/j.ygyno.2013.03.026. - DOI - PubMed
    1. Kang R, Tang D, Loze MT, Zeh HJ. Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE) Autophagy. 2011;7:91–3. https://doi.org/10.1038/cdd.2009.149. - DOI - PubMed
    1. Sun X, Tang D. HMGB1-dependent and -independent autophagy. Autophagy. 2014;10:1873–6. https://doi.org/10.4161/auto.32184. - DOI - PMC - PubMed
    1. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010;29:5299–310. https://doi.org/10.1038/onc.2010.261. - DOI - PMC - PubMed
    1. Liu Y, Prasad R, Wilson SH. HMGB1: roles in base excision repair and related function. Biochim Biophys Acta. 1799:119–30. https://doi.org/10.1016/j.bbagrm.2009.11.008. - DOI - PMC - PubMed